Monograph
A02BA53 - Famotidine, Combinations |
Propably not porphyrinogenic |
PNP |
Rationale
Famotidine: Partly unmetabolized. No clinical observations pointing to CYP inducing properties. Combined with two inorganic salts without CYP intarective properties
Chemical description
Famotidine: Used in ventricular hyperacidity (H2-receptor antagonist). About 70% excreted in urine in unmetabolized form. Partly metabolized in the liver to inactive sulfoxide metabolite. Impaired liver function does not seem to change the kinetics. Famotidine: South African list: use with care. French list: avoid
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Pepcidtwo 
Pepcidduo 
Manti 
Pepcid
© NAPOS 2025